Background: There has been intensive debate whether migraine with aura (MA) and migraine without aura (MO) should be considered distinct subtypes or part of the same disease spectrum. There is also discussion to what extent migraine cases collected in specialised headache clinics differ from cases from population cohorts, and how female cases differ from male cases with respect to their migraine. To assess the genetic overlap between these migraine subgroups, we examined genome-wide association (GWA) results from analysis of 23,285 migraine cases and 95,425 populationmatched controls. Methods: Detailed heterogeneity analysis of single-nucleotide polymorphism (SNP) effects (odds ratios) between migraine subgroups was performed for the 12 independent SNP loci significantly associated (p < 5 Â 10 À8 ; thus surpassing the threshold for genome-wide significance) with migraine susceptibility. Overall genetic overlap was assessed using SNP effect concordance analysis (SECA) at over 23,000 independent SNPs. Results: Significant heterogeneity of SNP effects (p het < 1.4 Â 10 À3 ) was observed between the MA and MO subgroups (for SNP rs9349379), and between the clinic-and population-based subgroups (for SNPs rs10915437, rs6790925 and rs6478241). However, for all 12 SNPs the risk-increasing allele was the same, and SECA found the majority of genomewide SNP effects to be in the same direction across the subgroups. Conclusions: Any differences in common genetic risk across these subgroups are outweighed by the similarities. Metaanalysis of additional migraine GWA datasets, regardless of their major subgroup composition, will identify new susceptibility loci for migraine.
Introduction
There has been extensive discussion in the migraine field concerning whether migraine with aura (MA) and migraine without aura (MO) are distinct subtypes or part of the same disease spectrum (1) (2) (3) (4) . Similar discussions concern how migraine cases ascertained from headache clinics compare to cases drawn from the general population, and how female migraine cases compare to male cases. In the current genomic age, a particularly important question is whether these major migraine subgroups have predominantly similar or distinct genetic aetiologies.
Results from the latest International Headache Genetics Consortium (IHGC) genome-wide association (GWA) meta-analysis of 23,285 migraine cases and 95,425 controls of European ancestry identified 142 single-nucleotide polymorphisms (SNPs) at 12 loci significantly associated (p < 5 Â 10 À8 ; thus surpassing the threshold for genome-wide significance) with migraine susceptibility. In addition, 1168 SNPs at 134 loci showed suggestive association (p < 1 Â 10 À5 ) with migraine (5) . In the original study, SNP effect (odds ratio (OR)) heterogeneity (Cochran's Q) and twotailed binomial tests were utilised to assess whether the effect size of the 146 index (i.e. most strongly associated independent) SNPs significantly differed between the MA and MO, clinic-and population-based, and female and male subgroups. Although minimal SNP effect heterogeneity was observed at the 146 loci, subgroup comparisons for the genome-wide significant loci indicated the effect sizes were predominantly larger in the MO cases compared to MA cases, larger in the clinic-based compared to population-based cases, and remarkably similar in female and male cases. These results held for the clinic-versus population-based and female versus male case comparisons for the 146 index SNPs. Analysis of the 146 index SNPs with concordant effect directions in the MA and MO subgroups showed that only 49% had a larger effect size in MO cases compared to MA cases, which does not differ significantly from that expected by chance (two-tailed binomial test p ¼ 0.93). However, given these 146 index SNPs were identified via a fixed-effect meta-analysis (which assumes that the true effect is the same in all studies), it is not surprising minimal heterogeneity was observed at these loci.
To more thoroughly assess the overall genetic overlap between these major migraine subgroups, we extend the analyses to SNP effects covering the entire autosome utilising our recently developed web-based application (SECA) to perform SNP effect concordance analysis (6) using GWA summary results from the IHGC (5) . Also, for the 12 genome-wide significant loci, we provide detailed results from SNP effect heterogeneity analyses between the MA and MO, clinicand population-based, and female and male subgroups.
Methods

Ethics statement
For all study cohorts, participation was based on informed consent. Each study was approved by local research ethics boards in the country where the study cohort was collected. See the original publication of the IHGC GWA meta-analysis for full details of ethics and consent procedures in each study cohort (5) .
Cohorts and sample collection
The IHGC GWA meta-analysis utilised SNP marker data from 23,285 cases with migraine and 95,425 controls of European ancestry from 29 studies, including five clinic-based studies, mainly compared to population-matched control samples with unknown migraine status, as well as 13 population-based cohorts (5) . To facilitate comparison of relative subgroup size and power, the effective sample size (N eff ) ¼ 4/(1/N cases þ 1/ N controls ) was calculated (7) . For a subset of the cohorts sufficiently detailed phenotype information was available to allow sub-classification into either of the two migraine subtypes, migraine with aura (MA: 5118 cases versus 74,239 controls, N eff ¼ 19,152) or migraine without aura (MO: 7107 cases versus 69,427 controls, N eff ¼ 25,788). The GWA data were also grouped into clinic-based (5175 cases versus 13,972 controls, N eff ¼ 15,105) versus population-based (18,110 cases versus 81,453 controls, N eff ¼ 59,264), and females-only (20, 202 cases versus 63,593 controls, N eff ¼ 61,326) versus males-only (3083 cases versus 31,832 controls, N eff ¼ 11,243). For more detailed descriptions of the cohorts, please see the original report (5) .
GWA results
Genome-wide SNP genotyping was performed independently in each cohort with the use of various standard genotyping technologies, and imputed for each study with reference to HapMap release 21 or 22 CEU phased genotypes (8) . Each study contributed summary statistic data from an association analysis performed using a frequentist additive model based on estimated SNP allelic dosages, adjusting for gender. SNPs were filtered on a per-study level based on inclusion criteria of minor allele frequency (MAF) >0.1% and imputation quality measures of I A > 0.6 (IMPUTE 2) (9) or r 2 > 0.3 (MaCH) (10) . In the meta-analysis, combined association data for 3,015,196 unique imputed and genotyped autosomal SNPs were analysed in a fixed-effect model using GWAMA (11) . Inconsistent SNP results were filtered out if they produced a very large heterogeneity coefficient (I 2 > 75%) or were present in less than five studies. Less than 2% of SNPs produced I 2 > 75%. There was little evidence of population stratification at the study level (genomic inflation factors, l 1.1), while moderate, but expected inflation was observed at the meta-analysis level (l ¼ 1.13) (12) . For a complete description, see the original publication of the 2013 IHGC migraine GWA meta-analysis (5) .
SNP effect heterogeneity analysis
Cochran's Q heterogeneity statistics and p values (P het ) were estimated via fixed-effect meta-analysis of the OR and 95% confidence interval (95% CI) for each SNP using GWAMA (11) . Heterogeneity p values (p het ) were estimated within and between the MA and MO, clinicand population-based, and female and male subgroups. When the number of studies combined is small (<10) (13) , the test has low power to detect heterogeneity if present, while if the number of studies is large, the test is likely to indicate heterogeneity, even if the absolute magnitude of the variability is unimportant (14) . Considering the large number and size of the individual migraine GWA studies, we used p het 0.05 to indicate nominal evidence for SNP effect heterogeneity.
SECA approach
To assess the overall genetic overlap between the MA and MO, clinic-and population-based, and female and male subgroups, SECA (6) compared three sets of two (i.e. (MA, MO), (clinic-based, population-based) and (females, males)) GWA summary results, each containing five essential columns: i) reference SNP cluster 'rs' identification (ID) (SNP), ii) effect allele (EA), iii) noneffect allele (NEA), iv) p value from association test (p), and v) OR for the EA relative to the NEA. To ensure consistency across the subgroup comparisons, only SNPs passing quality control (QC) in all subgroups were utilised (n ¼ 1,680,313).
SECA first aligned the SNP effects across the two GWA study summary results (dataset1, dataset2) to the same EA, and extracted a subset of independent SNPs via 'p value informed' linkage disequilibrium (LD) clumping using the PLINK program (15) . The approach iterates from the first to last SNP on each chromosome sorted from smallest to largest p value in dataset1 (P 1 ) that has not already been clumped (denoting this as the index SNP) and formed clumps of all other SNPs that are within 1 Mb and in LD (r 2 > 0.1) with the index SNP based on HapMap2 genotype data. A second round of LD clumping was performed to clump any of the round 1 index SNPs within 10 Mb of each other to account for long-range LD (r 2 > 0.1). The approach identifies the subset of independent SNPs with the most significant association p values (P 1 ) in dataset1.
Restricting to SNPs associated with p 1 (0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0) in dataset1, SECA performed Fisher's exact statistical tests using the R statistical package (16) to determine whether there is an excess of SNPs where the effect directions (OR) are concordant across dataset1 and dataset2 for the subset of SNPs associated with p 2 (0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0) in dataset2. For each of the 144 SNP subsets (generated using these 12 Â 12 p value threshold combinations), Fisher's exact statistical tests of SNP effects in dataset1 (i.e. OR 1 ) and dataset2 (OR 2 ) were performed on 2 Â 2 tables containing the number of SNPs with OR 1 < 1 and OR 2 < 1, OR 1 ! 1 and OR 2 < 1, OR 1 < 1 and OR 2 ! 1, and OR 1 ! 1 and OR 2 ! 1. The proportion of SNP subsets with concordant (Fisher's test (OR FT ) ! 1) and discordant (OR FT < 1) SNP effects, together with an empirical p value adjusted for testing all 144 subsets (p FTsig-permuted ), was calculated via permutation (1000 replicates) for the observed number of subsets (n FTsig ) with nominally significant concordance (OR FT ! 1 and p FT 0.05). A permuted p value was also estimated for the single most significant concordant test (p FTmin-permuted ). The permutation procedure first created uncorrelated datasets by randomly shuffling the observed SNP effect (OR 1 ) and corresponding p value (p 1 ) between SNPs in dataset1, and then repeats the analysis of the 144 SNP subsets. The SECA web-based application performs numerous other analyses -including pleiotropy tests agnostic to SNP effect direction, Q-Q and true discovery rate (TDR) plots, and 'pleiotropy-informed' conditional false discovery rate (FDR) results for dataset2 p values conditioned on dataset1 p values (6) -but here we report results only from the primary SNP effect concordance tests.
Comparison of SNP effect magnitude
An effectively random subset of independent SNPs were identified using an LD clumping approach analogous to above, except p values (p 1 ) were dummy-coded as 0.5 during the clumping rounds. SNP effect comparisons were performed for SNPs with concordant effects in the MA and MO, clinic-and population-based, and female and male subgroup pairs. Exact binomial statistical tests using the R statistical package (16) were performed to determine whether there was an excess proportion of SNPs with effect magnitudes larger in one subgroup (than the null proportion of 0.5) for the random subset of independent SNPs.
The global distribution of effect heterogeneity for the random subset of independent SNPs was also examined by generating Q-Q plots for Cochran's Q p values (p het ). Q-Q plots were constructed by ranking the p values from smallest to largest (the 'order statistics') and plotting them against their expected values under the null hypothesis of no association (sampled from the known chi-squared distribution). Deviations above the line of equality (drawn in white) indicate a preponderance of smaller p het values. To aid interpretation we have also calculated 95% confidence envelopes (shaded grey in all Q-Q plots). These are formed by calculating, for each order statistic, the 2.5th and 97.5th centiles of the distribution of the order statistic under random sampling and the null hypothesis.
Results
Associations results for index SNPs at the 12 genomewide significant loci reported in Anttila et al. (2013) (5) are presented in Table 1 . In addition to detailed results for the group or subgroup producing the most significant association p value (p assoc ), additional groups or subgroups producing genome-wide significant p assoc values are listed. As for Table 1 in the original study (5) , Table 1 lists the p value for Cochran's Q heterogeneity tests (p het ) for the group or subgroup producing the most significant P assoc value. To assess overall heterogeneity for the 12 index SNPs across all GWA cohorts, the association results from meta-analysis of all migraine cases are provided in Table 2 . Compared to Table 1 , which lists one SNP (rs2274316) with nominal heterogeneity (p het ¼ 1.6 Â 10 À2 ), Table 2 lists three SNPs (rs2274316, rs6790925, rs6478241) with nominal heterogeneity (1.2 Â 10 À2 p het 2.6 Â 10 À2 ) and one SNP (rs10915437) with highly significant heterogeneity (p het ¼ 8.1 Â 10 À5 ).
Comparing the 12 index SNP effects between the MA and MO subgroups (Table 3) , we found four SNPs (rs10915437, rs9349379, rs13208321 and rs10504861) with heterogeneous effect size (p het ¼ 4.4 Â 10 À3 , 3.2 Â 10 À4 , 4.9 Â 10 À2 and 4.5 Â 10 À3 , respectively). Apart from the effect for rs10915437, which was exclusively found in the MA subgroup, the effects for these heterogeneous SNPs were considerably stronger in the MO compared to MA subgroup. Comparing the 12 index SNPs between the clinic-and population-based subgroups (Table 4) , we found eight SNPs (rs10915437, rs2274316, rs7577262, rs6790925, rs9349379, rs13208321, rs4379368 and rs6478241) with heterogeneous effects (p het ¼ 8.1 Â 10 À6 , 3.5 Â 10 À3 , 1.1 Â 10 À2 , 2.0 Â 10 À5 , 2.6 Â 10 À2 , 2.0 Â 10 À2 , 2.0 Â 10 À2 and 2.7 Â 10 À5 , respectively). Although concordant, these eight heterogeneous SNP effects were all considerably larger in the clinic-based subgroup compared to the population-based subgroup. In contrast, the 12 index SNP effects were remarkably homogenous in the female and male subgroups ( Table 5 ). After adjusting for three sets of 12 heterogeneity tests, significant heterogeneity of SNP effects (p het < 1.4 Â 10 À3 ) remains between the MA and MO subgroups (rs9349379), and clinic-and population-based subgroups (rs10915437, rs6790925 and rs6478241).
Results from SECA (online Supplementary Tables)  comparing MA subgroup ORs for the 23,367 index SNPs with the most significant MA association p values (p assoc ) to the ORs in the MO subgroup indicated the SNP effects were highly concordant across these subgroups. The total number of SNP subsets with nominally significant concordant effects (i.e. Fisher's tests with OR FT ! 1 and p FT 0.05) was 144. Out of 1000 replicates, 0 produced 144 subsets with nominally significant concordant effects (p FTsigpermuted ¼ 9.9 Â 10 À4 ; 95% CI: 5.1 Â 10 À5 -5.6 Â 10 À3 ). The subset producing the most significant concordance test was for SNPs with MA p assoc 0.3 and MO p assoc 0.5 (OR FT ¼ 4.4; p FTmin ¼ 2.3 Â 10 À256 ). Analogous concordance was obtained comparing ORs for the 23,162 index SNPs with the most significant MO p assoc to the ORs in the MA subgroup; here the subset producing the most significant concordance test was for SNPs with MO p assoc 0.3 and MA p assoc 0.6 (OR FT ¼ 3.8; p FTmin ¼ 1.3 Â 10 À248 ).
Given that the 2013 IHGC MA and MO subgroup analyses utilised overlapping controls, the MA and MO SNP effect estimates are not independent of each other. Furthermore, because 64,847 (87%) of the total 74,239 MA controls were also MO controls, and 93% of the total 69,427 MO controls were also MA controls, the SECA concordance analysis will be severely biased in favour of concordance -driven by the near identical control allele frequencies being compared to the less similar MA and MO case frequencies. Therefore, SECA was re-run using the independent clinic-based MA (17) and clinic-based MO (18) GWA datasets from the 2013 study (5) .
Results from SECA comparing the clinic-based MA subgroup (2849 cases versus 9392 controls, N eff ¼ 8744) ORs for the 23,182 index SNPs with the most Results from SECA comparing ORs for the 23,392 index SNPs with the most significant clinic-based p assoc to the ORs in the population-based subgroup indicated the SNP effects were highly concordant across these subgroups. All 144 SNP subsets produced nominally significant concordance (p FTsig-permuted ¼ 9.9 Â 10 À4 ; 95% CI: 5.1 Â 10 À5 À 5.6 Â 10 À3 ). The subset producing the most significant concordance test was for SNPs with clinic-based p assoc 0.1 and population-based p assoc 0.4 (OR FT ¼ 1.7; p FTmin ¼ 7.1 Â 10 À21 ). Analogous concordance was obtained comparing ORs for the 23,374 index SNPs with the most significant population-based p assoc to the ORs in the clinic-based subgroup; here the subset producing the most significant concordance test was for SNPs with population-based p assoc 0.2 and clinic-based p assoc 0.2 (OR FT ¼ 1.8; p FTmin ¼ 7.0 Â 10 À19 ).
Results from SECA comparing ORs for the 23,276 index SNPs with the most significant female subgroup p assoc to the ORs in the male subgroup indicated the SNP effects were highly concordant across these subgroups. All 144 SNP subsets produced nominally significant concordance (p FTsig-permuted ¼ 9.9 Â 10 À4 ; 95% CI: 5.1 Â 10 À5 -5.6 Â 10 À3 ). The subset producing the most significant concordance test was for SNPs with female p assoc 0.3 and male p assoc 0.7 (OR FT ¼ 2.0; p FTmin ¼ 9.6 Â 10 À78 ). Analogous concordance was obtained comparing ORs for the 23,266 index SNPs with the most significant male p assoc to the ORs in the female subgroup; here the subset producing the most significant concordance test was for SNPs with male p assoc 0.3 and female p assoc 0.5 (OR FT ¼ 2.1; p FTmin ¼ 1.5 Â 10 À65 ).
Global comparisons of SNP effect magnitude for concordant effects are summarised in Table 6 . The random set of independent SNPs encompassed a total of 23,795 SNPs, of which 12,541 SNPs had concordant effects across the clinic-based MA and clinic-based MO subgroups. Of these 12,541 SNPs the effect magnitude was greater in the MO subgroup for 6780 (54%) SNPs (two-tailed binomial test p BT ¼ 9.4 Â 10 À20 ). Of the 12,174 SNPs with concordant effects across the clinicbased and population-based subgroups, the effect magnitude was greater in the clinic-based subgroup for 8529 (70%) SNPs (p BT < 4.9 Â 10 À324 ). Among the 12,564 SNPs with concordant effects across the female and male subgroups, the effect magnitude was greater in the male subgroup for 9420 (75%) SNPs (p BT < 4.9 Â 10 À324 ). Q-Q plots (online Supplementary  Figures 1-4 ) of effect heterogeneity (Cochran's Q) p values between the major migraine subgroups indicate no global heterogeneity between the clinic-based MA and MO (online Supplementary Figure 1) , and female and male subgroups (online Supplementary Figure 4) in the total random set of 23,795 independent SNPs, whereas online Supplementary Figure 2 suggests global heterogeneity of effects (represented by an excess of small p values above the null identify line) between the clinic-based and population-based subgroups in the total random set of 23,795 independent SNPs. However, this excess is not present in the random set of 12,174 independent SNPs with concordant effects (online Supplementary Figure 3 ). SNP: single nucleotide polymorphism; Total: total number of SNPs with concordant effect across Subgroup 1 and Subgroup 2; OR 1 > OR 2 , number of SNPs with odds ratio (OR) for Subgroup 1 greater than OR for Subgroup 2 (as a proportion of Total is also provided in brackets); p BT : two-tailed p value from an exact binomial test of observing the number of SNPs with OR 1 > OR 2 by chance.
